Theresa Matkovits - Dec 15, 2023 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Chief Development Officer
Signature
/s/ Keith A. Kucinski, attorney-in fact for Theresa Matkovits
Stock symbol
MTNB
Transactions as of
Dec 15, 2023
Transactions value $
$0
Form type
4
Date filed
12/15/2023, 09:46 PM
Previous filing
Dec 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +1.3M $0.00 1.3M Dec 15, 2023 Common Stock 1.3M $0.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.